Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery
Nenhuma Miniatura disponível
Data
2006-07-17
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Resenha
Direito de acesso
Acesso restrito
Resumo
The use of the nasal route for drug delivery has attracted much interest in recent years in the pharmaceutical field. Local and principally systemic drug delivery can be achieved by this route of administration. But the nasal route of delivery is not applicable to all drugs. Polar drugs and some macromolecules are not absorbed in sufficient concentration due to poor membrane permeability, rapid clearance and enzymatic degradation into the nasal cavity. Thus, alternative means that help overcome these nasal barriers are currently in development. Absorption enhancers such as phospholipids and surfactants are constantly used, but care must be taken in relation to their concentration. Drug delivery systems including liposomes, cyclodextrins, micro- and nanoparticles are being investigated to increase the bioavailability of drugs delivered intranasally. This review article discusses recent progress and specific development issues relating to colloidal drug delivery systems in nasal drug delivery. © 2006 Bentham Science Publishers Ltd.
Descrição
Palavras-chave
Colloidal drug delivery systems , Nasal bioavailability , Nasal delivery , antihistaminic agent , antimigraine agent , barbital , beclometasone , beclometasone dipropionate , budesonide , buprenorphine , cefazolin , corticosteroid derivative , cyclodextrin derivative , estradiol , flunisolide , fluticasone propionate , gentamicin , glyceryl trinitrate , hydralazine , insulin , liposome , metoprolol , mometasone furoate , nanoparticle , penicillin G , pentobarbital , phenobarbital , phospholipid derivative , progesterone , propranolol , surfactant , testosterone , triamcinolone acetonide , unindexed drug , brain , colloid , drug absorption , drug bioavailability , drug clearance , drug delivery system , drug formulation , enzyme degradation , human , macromolecule , membrane permeability , nonhuman , nose cavity , priority journal , review , unspecified side effect , Administration, Intranasal , Animals , Biological Availability , Colloids , Drug Carriers , Drug Delivery Systems , Humans , Liposomes , Nanostructures , Vaccines
Idioma
Inglês
Como citar
Current Drug Delivery, v. 3, n. 3, p. 275-285, 2006.